---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-095852"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2021-07-26T23:59:59+00:00"
generated_at: "2026-06-30T02:31:34.748156+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Appoints Brian Strem as President & CEO; signs non-binding LOI to acquire Bayon Therapeutics

## Summary
- Brian M. Strem appointed President and CEO effective July 26, 2021; Franz Obermayr returns to EVP Clinical Development.
- Strem receives $400K annual base salary, target bonus of 50% of base, and option to purchase 100K shares vesting over 3 years.
- EyeGate enters non-binding term sheet to acquire Bayon Therapeutics for closing consideration of 50K shares and earnout up to $7.1M or ~2.2M shares.
- Strem is co-founder of Bayon and owns ~28% equity; transaction subject to definitive agreement and milestone conditions.

## SEC filing metadata
- accession: 0001104659-21-095852
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2021-07-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000110465921095852/0001104659-21-095852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000110465921095852/tm2123169-1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-095852
- JSON: https://secwatch.observer/filing/0001104659-21-095852.json
- Plain text: https://secwatch.observer/filing/0001104659-21-095852.txt

## Key facts
- Executive change
  Brian M. Strem was appointed as Class I Director at KIORA PHARMACEUTICALS INC.
  - Action: appointed
  - Role: Class I Director
  source text: the Board, upon the recommendation of its Nominating and Corporate Governance Committee, increased the size of the Board from seven to eight members, and appointed Dr. Strem as a Class I director to fill the resulting vacancy, in each case effective as of the Effective Date
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000110465921095852/0001104659-21-095852-index.htm
- Executive change
  Brian M. Strem was appointed as President and Chief Executive Officer at KIORA PHARMACEUTICALS INC.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On July 23, 2021, the Board of Directors (the “Board”) of EyeGate Pharmaceuticals, Inc. (the “Company”) appointed Brian M. Strem, Ph.D. as President and Chief Executive Officer of the Company, effective as of July 26, 2021 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000110465921095852/0001104659-21-095852-index.htm
- Executive change
  Franz Obermayr changed role as EVP Clinical Development at KIORA PHARMACEUTICALS INC.
  - Action: resumed
  - Role: EVP Clinical Development
  source text: Franz Obermayr, Ph.D., who has served as the Company’s Acting Chief Executive Officer since February 2021, resumed his prior role with the Company as its EVP Clinical Development, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000110465921095852/0001104659-21-095852-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.